IL-1 Beta Beckons In Type 2 Diabetes and Potentially, Cardiovascular Disease
This article was originally published in Start Up
Executive Summary
The IL-1 receptor has long been a target for autoimmune therapies. Now, data are emerging using several drugs, notably IL-1 beta antibodies, which support the general notion that blocking the IL-1 pathway could be useful in treating diabetes, particularly in patients at risk of cardiovascular disease. Indeed, one recent paper suggests that it could even be a therapeutic strategy to prevent heart failure after acute AMI.
You may also be interested in...
Altering The Insulin Resistance System
With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.
Altering The Insulin Resistance System
With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.
FDA To Ask Advisory Committees To Review Phase IV Safety Trial Designs
FDA is preparing to take proposals for large post marketing studies to its drug advisory committees to solicit outside advice and counsel on the design and term of the new mandatory studies